ONCOLOGY PROGRAM
Rgenta is pioneering the development of orally available small molecules that target RNA, enabling the elimination of oncogenic proteins previously considered undruggable—such as MYB, a key driver of both solid tumors and hematologic cancers.
CNS PROGRAM
Our unique approach directly targets the root cause of repeat expansion diseases (REDs)—genetic disorders, such as Huntington’s disease, that are driven by the abnormal expansion of repeat sequences within affected genes. This expansion leads to the production of defective proteins, and our strategy aims to address this fundamental genetic dysfunction.
Rgenta's goal is to dramatically transform the treatment of incurable diseases with best-in-class RNA-targeted therapies that unlock new possibilities for patients
